Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF

Journal of Neurology

Volumn 254, Issue 2, 2007, Pages 160-168

  Kuhle, Jens ^a   Lindberg, Raija L P ^a   Regeniter, Axel ^a   Mehling, Matthias ^a   Hoffmann, Francine ^a   Reindl, Markus ^b   Berger, Thomas ^b   Radue, Ernst W ^a   Leppert, David ^a,c   Kappos, Ludwig ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Antimyelin antibodies; Clinically isolated syndrome; Multiple sclerosis; Prognosis

Indexed keywords

IMMUNOGLOBULIN G; MYELIN BASIC PROTEIN ANTIBODY; MYELIN OLIGODENDROGLIAL GLYCOPROTEIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ARTICLE; BRAIN DAMAGE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CYTOLOGY; CLINICALLY ISOLATED SYNDROME; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE PREDISPOSITION; FEMALE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN PRODUCTION; INFLAMMATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; WESTERN BLOTTING;

ADULT; ANTIBODIES; CHI-SQUARE DISTRIBUTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; MYELIN-ASSOCIATED GLYCOPROTEIN; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 33847677762     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-006-0299-4     Document Type: Article

References (46)

1. Achiron A, Barak Y (2000) Multiple sclerosis-from probable to definite diagnosis: a 7-year prospective study. Arch Neurol 57:974-979
2. Andersson M, varez-Cermeno J, Bernardi G, Cogato I, Fredman P, Frederiksen J, Fredrikson S, Gallo P, Grimaldi LM, Gronning M (1994) Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 57:897-902
3. Baumann N, Pham-Dinh D (2001) Biology of Oligodendrocyte and Myelin in the Mammalian Central Nervous System. Physiol Rev 81:871-927
4. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349:139-145
5. Bonifacio E, Lampasona V, Bingley PJ (1998) IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigens. J Immunol 161:2648-2654
6. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346:158-164
7. Brunner C, Lassmann H, Waehneldt TV, Matthieu JM, Linington C (1989) Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2′,3′-cyclic nucleotide 3′-phosphodiesterase in the CNS of adult rats. J Neurochem 52:296-304
8. Cepok S, Jacobsen M, Schock S, Omer B, Jaekel S, Boddeker I, Oertel WH, Sommer N, Hemmer B (2001) Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 124:2169-2176
9. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H, Seeldrayers P, Sorensen PS, Rovaris M, Martinelli V, Hommes OR (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357:1576-1582
10. Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126:770-782
11. Egg R, Reindl M, Deisenhammer F, Linington C, Berger T (2001) Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. Mult Scler 7:285-289
12. Eriksson M, Andersen O, Runmarker B (2003) Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 9:260-274
13. Farlow MR, Edwards MK, Kolar OJ, Stevens JC, Yu PL (1987) Magnetic resonance imaging in multiple sclerosis: analysis of correlations to peripheral blood and spinal fluid abnormalities. Neurology 37:1527-1530
14. Frederiksen JL, Larsson HB, Olesen J (1992) Correlation of magnetic resonance imaging and CSF findings in patients with acute monosymptomatic optic neuritis. Acta Neurol Scand 86:317-322
15. Gaertner S, de Graaf KL, Greve B, Weissert R (2004) Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology 63:2381-2383
16. Galboiz Y, Miller A (2002) Immunological indicators of disease activity and prognosis in multiple sclerosis. Curr Opin Neurol 15:233-237
17. Genain CP, Cannella B, Hauser SL, Raine CS (1999) Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 5:170-175
18. Genain CP, Nguyen MH, Letvin NL, Pearl R, Davis RL, Adelman M, Lees MB, Linington C, Hauser SL (1995) Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Invest 96:2966-2974
19. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343:898-904
20. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R, for the BENEFIT Study Group (2006) Treatment with interferon beta 1-6 delays conversion to clinically definite and McDonald Ms in patients with clinically isolated syndromes. Neurology 67:1242-1249
21. Keir G, Luxton RW, Thompson EJ (1990) Isoelectric focusing of cerebrospinal fluid immunoglobulin G: an annotated update. Ann Clin Biochem 27 (Pt 5):436-443
22. Kerlero de RN, Honegger P, Lassmann H, Matthieu JM (1990) Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin/oligodendrocyte glycoprotein. J Neurochem 55:583-587
23. Kurtzke JF, Beebe GW, Nagler B, Kurland LT, Auth TL (1977) Studies on the natural history of multiple sclerosis-8. Early prognostic features of the later course of the illness. J Chronic Dis 30:819-830
24. Lampasona V, Franciotta D, Furlan R, Zanaboni S, Fazio R, Bonifacio E, Comi G, Martino G (2004) Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology 62:2092-2094
25. Lee KH, Hashimoto SA, Hooge JP, Kastrukoff LF, Oger JJ, Li DK, Paty DW (1991) Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 41:657-660
26. Lim ET, Berger T, Reindl M, Dalton CM, Fernando K, Keir G, Thompson EJ, Miller DH, Giovannoni G (2005) Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Multi Scler 11:492-494
27. Linington C, Bradl M, Lassmann H, Brunner C, Vass K (1988) Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 130:443-454
28. Link H, Tibbling G (1977) Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest 37:397-401
29. Linnington C, Webb M, Woodhams PL (1984) A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody. J Neuroimmunol 6:387-396
30. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H (1996) Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 6:259-274
31. Miller DH, Ormerod IE, Gibson A, du Boulay EP, Rudge P, McDonald WI (1987) MR brain scanning in patients with vasculitis: differentiation from multiple sclerosis. Neuroradiology 29:226-231
32. Morrissey SP, Miller DH, Kendall BE, Kingsley DP, Kelly MA, Francis DA, MacManus DG, McDonald WI (1993) The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 116 (Pt 1):135-146
33. O'Connor KC, Chitnis T, Griffin DE, Piyasirisilp S, Bar-Or A, Khoury S, Wucherpfennig KW, Hafler DA (2003) Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol 136:140-14833
34. Olsson T (1994) Multiple sclerosis: cerebrospinal fluid. Ann Neurol 36 Suppl:S100-S102
35. Ormerod IE, Bronstein A, Rudge P, Johnson G, Macmanus D, Halliday AM, Barratt H, Du Boulay EP, Kendal BE, Moseley IF,. (1986) Magnetic resonance imaging in clinically isolated lesions of the brain stem. J Neurol Neurosurg Psychiatry 49:737-743
36. Pagany M, Jagodic M, Schubart A, Pham-Dinh D, Bachelin C, Baron van EA, Lachapelle F, Olsson T, Linington C (2003) Myelin oligodendrocyte glycoprotein is expressed in the peripheral nervous system of rodents and primates. Neurosci Lett 350:165-168
37. Reiber H (1994) Flow rate of cerebrospinal fluid (CSF)-a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases [see comments]. J Neurol Sci 122:189-203
38. Reindl M, Linington C, Brehm U, Egg R, Dilitz E, Deisenhammer F, Poewe W, Berger T (1999) Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 122 (Pt 11):2047-2056
39. Schluesener HJ, Sobel RA, Linington C, Weiner HL (1987) A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 139:4016-4021
40. Sharief MK, Thompson EJ (1991) The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis. Ann Neurol 29:147-151
41. Stefferl A, Brehm U, Linington C (2000) The myelin oligodendrocyte glycoprotein (MOG): a model for antibody-mediated demyelination in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neural Transm Suppl 123-133
42. Storch MK, Stefferl A, Brehm U, Weissert R, Wallstrom E, Kerschensteiner M, Olsson T, Linington C, Lassmann H (1998) Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 8:681-694
43. Sun J, Link H, Olsson T, Xiao BG, Andersson G, Ekre HP, Linington C, Diener P (1991) T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J Immunol 146:1490-1495
44. Uitdehaag BM, Kappos L, Bauer L, Freedman MS, Miller D, Sandbrink R, Polman C (2005) Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization. Multi Scler 11:227-231
45. Villoslada P, Abel K, Heald N, Goertsches R, Hauser SL, Genain CP (2001) Frequency, heterogeneity and encephalitogenicity of T cells specific for myelin oligodendrocyte glycoprotein in naive outbred primates. Eur J Immunol 31:2942-2950
46. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC (1989) The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112 (Pt 6):1419-1428